EDSA
Edesa BiotechFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
EDSA still has upside optionality because paridiprubart showed statistically significant mortality benefit in the February 24, 2026 8-K, and the company also has external program support through government-backed funding and study activity [#8-K-2026-02-24] [#10-Q-2026-02-13].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Dilutive financing or additional ATM usage
Momentum
15
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum15 · Δ7d -2.2
Value41 · Δ7d +0.0
Sentiment31 · Δ7d +3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
15
26% active weight
Current posture
7d trendImproving
Δ7d
-2.2
Δ21d
+13.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
31
34% active weight
Current posture
7d trendImproving
Δ7d
+3.8
Δ21d
+1.9
Why this grade
Composite grade F. Momentum 15.2 / Value 41.1 / Sentiment 30.7
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$56.07M
Beta
0.21
Shares Out
9.63M
P/E (TTM) · Derived
-4.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.76
Rev YoY
-100.0%
EPS YoY
+64.7%
Gross Margin
-24138.0%
Op Margin
-
Net Debt
-$10.79M
Current Ratio
4.76
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology